Accepted Manuscript

Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible *h*MAO-A inhibitors

Nafiz Öncü Can, Derya Osmaniye, Serkan Levent, Begüm Nurpelin Sağlık, Büşra Korkut, Özlem Atlı, Yusuf Özkay, Zafer Asım Kaplancıklı

PII: S0223-5234(17)31019-X

DOI: 10.1016/j.ejmech.2017.12.013

Reference: EJMECH 9991

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 21 July 2017

Revised Date: 20 October 2017

Accepted Date: 4 December 2017

Please cite this article as: Nafiz.Öü. Can, D. Osmaniye, S. Levent, Begü.Nurpelin. Sağlık, Büş. Korkut, Ö. Atlı, Y. Özkay, Zafer.Ası. Kaplancıklı, Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible *h*MAO-A inhibitors, *European Journal of Medicinal Chemistry* (2018), doi: 10.1016/j.ejmech.2017.12.013.

Competitive, Reversible and Selective *h*MAO-A Inhibitor

IC_{50}= 0.011 µM against *h*MAO-A; IC_{50}: 17.615 µM



Compound 3h

Possess Good Predicted ADME Profile
&
Notable interactions in the *h*MAO-A active site

Non-cytotoxic (NIH3T3 IC_{50}> 1000 µM)
&
Non-genotoxic